Navigation Links
EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
Date:10/8/2008

Medical patient noncompliance is a major healthcare issue. The Emap typology provides a new patient assessment program to determine the compliance personality of individuals and then targeted guidance for how to best communicate healthcare information to each of the six compliance Profiles

(PRWEB) October 8, 2008 -- www.enrichmap.com [EnrichMap __title__ Click this link.] announces new program to reduce medical www.enrichmap.com [patient noncompliance __title__ Click this link.]and offers healthcare organizations a limited trial test opportunity.

EnrichMap has developed a new methodology to identify the www.enrichmap.com [medical compliance personality] of individual patients and then employ a more targeted, personalized approach to increasing compliance. EnrichMap is seeking organizations in the healthcare industry to conduct demonstration tests of the Emap Profile to predict and manage patient compliance. The trial programs are available for a limited time at no cost to the clients.

The Emap research indicates that each person has a core compliance personality which shapes their attitudes and behavior in adhering to healthcare regimens. The Emap Profile identifies six Compliance Personality Groups, each of which can now be addressed with a targeted approach to healthcare communications and treatment styles that help to enlist the patient to be more responsive and participatory in their own healthcare program.

Clinical trial researchers can use Emap to determine the likelihood of a subject completing a trial and following a defined protocol. Healthcare providers and insurance companies can suggest protocols, communications and treatment styles that better match the nature of the patient, to increase the likelihood of achieving desired outcomes and reduce costs.

Dr. Allan Showalter and several colleagues, after studying noncompliance for many years in their own practices, founded EnrichMap to create a program dedicated to improving patient compliance. According to Dr. Showalter, "The opposite of treatment www.enrichmap.com [adherence] is not treatment nonadherence. The opposite of treatment adherence is treatment failure. Despite an age-old awareness of healthcare noncompliance, we've made little notable progress in understanding the basic elements of patient noncompliance. The guiding principle of the Emap Profile is that to address noncompliance in the most practical manner, it is far more effective and efficient to change the nature of the medical communications process than to try to change the nature of the patient."

Advance knowledge of a patient's compliance personality enables the healthcare provider/manager to target existing patient management resources using the Emap Compliance Communications Guide to identify specific patient intervention methods. The EMap typology can be viewed as a low-cost extension of the traditional patient history, using a simple questionnaire that can be completed in a few minutes, and the Emap statistical analysis which assigns the patient to one of the six distinct Emap profiles.

EnrichMap is seeking organizations to conduct research projects to demonstrate the benefits that Emap can provide in their own healthcare applications. The Emap program is available to clinicians, clinical trial researchers, healthcare management systems, employee wellness programs, insurance providers, and others invested in improving patient compliance and reducing healthcare costs. For more information about a limited use demonstration study contact Fred Ellman at (262) 764-0652

###

Read the full story at http://www.prweb.com/releases/2008/10/prweb1434244.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):